Distribution of diagnoses in the population positive for anti-Ro52, anti-Ro60, and anti-SSB as defined by line immunoassay in relation to the immunodiffusion result
| n | SLE % (95% CI) | CLE % (95% CI) | SCl % (95% CI) | RA % (95% CI) | PM/DM % (95% CI) | pSS % (95% CI) | Other % (95% CI) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| CLE, cutaneous lupus without systemic involvement; ID, immunodiffusion; PM/DM, polymyositis/dermatomyositis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SCl, scleroderma; SLE, systemic lupus erythematosus. | ||||||||||
| Ro52+ | Ro60+ | SSB+ | 86 | 55.8 | 5.8 | 1.2 | 5.8 | 0 | 20.9 | 10.5 |
| ID SSA+ and IDSSB+ | 26 | 69.2 (48.2 to 85.7) | 0 | 3.8 (0.1 to 19.6) | 7.7 (0.9 to 25.1) | 0 | 19.2 (6.6 to 39.4) | 0 | ||
| ID SSA+ and ID SSB− | 39 | 64.1 (47.2 to 78.8) | 5.1 (0.6 to 17.3) | 0 | 2.6 (0.06 to 13.5) | 0 | 15.4 (5.9 to 30.5) | 12.8 (4.3 to 27.4) | ||
| ID SSA− and ID SSB+ | 15 | 13.3 (1.7 to 40.5) | 20.0 (4.3 to 48.1) | 0 | 6.7 (0.2 to 32.0) | 0 | 46.7 (21.3 to 73.4) | 13.3 (1.7 to 40.5) | ||
| ID SSA− and ID SSB− | 6 | 50.0 (11.8 to 88.2) | 0 | 0 | 16.7 (0.4 to 64.1) | 0 | 0 | 33.3 (4.3 to 77.7) | ||